DIASORIN LAUNCHES PRIMER PAIR FOR CANDIDA AURIS IN THE US MARKET

Saluggia - November 11, 2019 - DiaSorin (FTSE MIB: DIA) announced today that it has released a new primer pair for use in laboratory-developed molecular tests that targets the yeast Candida auris. The primer pairs are classified as Analyte Specific Reagents (ASRs), which can be used by high-complexity laboratories to develop their own laboratory developed tests (LDTs) in the United States.

Candida auris, according to the CDC, is a quickly emerging drug-resistant yeast that spreads in healthcare facilities and is a serious global health threat. It is often difficult to identify with non-molecular methods, with misidentification leading to poor and costly patient management.

The yeast is often multi-drug resistant and has caused recent outbreaks in hospitals and long-term care facilities across the U.S and in more than 20 countries. Since the organism is becoming more common, effective and timely identification of the organism is required for mitigation of this threat.

“We are proud to offer the first commercially available molecular ASR targeting Candida auris” said Michelle Tabb, Chief Scientific Officer at DiaSorin Molecular LLC. “DiaSorin strives to listen and respond to customers regarding their needs for molecular infectious disease products.”

DiaSorin
Headquartered in Italy and listed in the FTSE MIB Index, DiaSorin is a global leader in the In Vitro Diagnostic (IVD) field. For over 50 years, the Company has been developing, producing and marketing reagent kits for IVD worldwide. The Group has a presence on the 5 continents with 25 companies, 5 foreign branches, 6 manufacturing facilities and 5 research centers throughout the world. Through constant investments in research and development, and using its own distinctive expertise in the field of immunodiagnostics to deliver a high level of innovation, DiaSorin offers today the broadest range of specialty tests available in the immunodiagnostics market and new tests in the molecular diagnostics markets, which identify DiaSorin Group as the “Diagnostic Specialist”.

For additional information, please contact:

Riccardo Fava
Corporate Vice President Communication & Investor Relations
Tel: +39.0161.487988
riccardo.fava@diasorin.it